Welcome to our dedicated page for Rubius Therapeutics news (Ticker: RUBY), a resource for investors and traders seeking the latest updates and insights on Rubius Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rubius Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rubius Therapeutics's position in the market.
Rubius Therapeutics (Nasdaq: RUBY) has announced promising preclinical data for its lead clinical oncology program, RTX-240, during the SITC Annual Meeting. RTX-240 is an engineered allogeneic red cell therapeutic aimed at activating T and NK cells to enhance anti-tumor responses. The data showed RTX-240's efficacy in expanding CD8 T and NK cells, and demonstrated potent NK cell activity against leukemia cells. The company is currently enrolling patients in a Phase 1/2 clinical trial targeting relapsed/refractory solid tumors and acute myeloid leukemia, evaluating safety and anti-tumor activity.
Rubius Therapeutics (Nasdaq:RUBY) has initiated dosing in a Phase 1/2 clinical trial of RTX-240 for treating acute myeloid leukemia (AML) and advanced solid tumors. This allogeneic cellular therapy aims to activate NK and T cells, enhancing the body's immune response against cancer. The trial seeks to establish safety, tolerability, and pharmacodynamics. AML remains a challenging condition with limited therapeutic options, particularly for relapsed or refractory cases, which have a five-year survival rate of approximately 10%. Successful outcomes could position RTX-240 as a novel treatment approach.
Rubius Therapeutics (Nasdaq:RUBY) will report its third quarter 2020 financial results on November 9, 2020, before the market opens.
The company focuses on pioneering Red Cell Therapeutics™, a novel class of cellular medicines aimed at treating cancer and autoimmune diseases. Notably, Rubius's manufacturing site was recognized as one of the Top 5 Best Places to Work in Rhode Island for medium-sized companies in 2020.
Rubius Therapeutics (Nasdaq:RUBY) announced new preclinical data on RTX-321, an artificial antigen-presenting cell therapy targeted at HPV 16-positive cancers. Presented at the FOCIS Virtual Annual Meeting and AACR Tumor Immunology Conference, RTX-321 demonstrates a dual mechanism by enhancing HPV 16-specific T cell responses while stimulating broader innate and adaptive immunity. This may lead to improved anti-tumor responses and long-term memory against cancer recurrence, addressing a critical need in advanced HPV 16-associated cancers.
Rubius Therapeutics (Nasdaq:RUBY) announced its participation in the Society for Immunotherapy of Cancer's 35th Annual Meeting, where it will present preclinical data on RTX-240, an engineered Red Cell Therapeutic™ aimed at generating an anti-tumor immune response.
RTX-240 is designed to activate and expand T and NK cells in patients with relapsed/refractory solid tumors and acute myeloid leukemia. Patient recruitment for the Phase 1/2 trial is ongoing, bolstered by a cleared Investigational New Drug application.
Rubius Therapeutics (Nasdaq: RUBY) announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on October 5, 2020, at 4:00 p.m. ET. The event will feature a live audio webcast available on the company's website, with an archived replay accessible for 90 days. Rubius is focused on developing Red Cell Therapeutics™ for cancer and autoimmune diseases.
Rubius Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: RUBY), will have its Chief Scientific Officer, Laurence Turka, M.D., participating in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on October 5, 2020, at 4:00 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with an archived replay available for 90 days post-event. Rubius is focused on developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases using its proprietary RED PLATFORM® technology.
Rubius Therapeutics (Nasdaq:RUBY) announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer, effective immediately. With over 20 years of experience in the biopharmaceutical sector, Carmona's background includes leadership roles at Radius Health and Novartis. The company is advancing its RTX-240 Phase 1 clinical trial and preparing to file an Investigational New Drug application for RTX-321 by year-end. CEO Pablo J. Cagnoni expressed confidence in Carmona's financial expertise as key to driving the company's clinical data generation and broad pipeline development.
Rubius Therapeutics (Nasdaq:RUBY) announced the appointment of Jose “Pepe” Carmona as chief financial officer, bringing over 20 years of biopharmaceutical experience. This change comes as the company progresses in its RTX-240 Phase 1 clinical trials for solid tumors and acute myeloid leukemia. Rubius is also on track to file an Investigational New Drug application for RTX-321 by year-end. Carmona's expertise in finance and operations is expected to bolster Rubius’ clinical data generation and support its pipeline of Red Cell Therapeutics™ aimed at cancer and autoimmune diseases.
Rubius Therapeutics (Nasdaq: RUBY) announced participation in two upcoming investor conferences. Laurence Turka, M.D., will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference on September 14, 2020, at 11:30 a.m. ET. Additionally, Pablo J. Cagnoni, M.D., will engage in a fireside chat at the 20th Annual Morgan Stanley Virtual Global Healthcare Conference on September 16, 2020, at 1:15 p.m. ET. Both events will be available via live audio webcast and archived for 90 days.
FAQ
What is the market cap of Rubius Therapeutics (RUBY)?
